Fed. Circ. Mulls Undoing Mylan Win In Biogen Drug IP Fight
By Britain Eakin and Nadia Dreid ( December 8, 2020, 10:25 PM EST) -- Two Federal Circuit judges on Tuesday suggested that a Mylan attorney's argument that a Biogen patent on multiple sclerosis drug Tecfidera failed to disclose the efficacy of a specific dosage is an enablement issue, calling into question whether the district court wrongly invalidated it for lacking written description support....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.